PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additio...
April 16 2019 - 4:01PM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for orphan diseases, today
announced the closing of its underwritten public offering of
4,124,475 shares of its common stock, which includes the full
exercise of the underwriters’ option to purchase an additional
537,975 shares, at a price to the public of $12.00 per share. The
gross proceeds from the offering were $49.5 million, before
deducting underwriting discounts and commissions and estimated
offering expenses payable by PhaseBio.
Citigroup, Cowen and Stifel acted as joint book-running managers
for the offering. Needham & Company acted as co-manager for the
offering.
The offering was made only by means of a prospectus. The final
prospectus related to the offering may be obtained from Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, telephone: 1-800-831-9146; or
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus
Department, telephone: 1-631-274-2806, or fax: 1-631-254-7140.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Investor Contact: John Sharp PhaseBio
Pharmaceuticals, Inc. Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
Media Contact: Sarah Hall 6 Degrees (215)
313-5638 shall@6degreespr.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Apr 2023 to Apr 2024